Ginkgolides protect against amyloid-β

Molecular Neurodegeneration

Volumn 3, Issue 1, 2008, Pages

  Bate, Clive ^a   Tayebi, Mourad ^a   Williams, Alun ^a  

^a ROYAL VETERINARY COLLEGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GINKGO BILOBA;

EID: 40149094037     PISSN: None     EISSN: 17501326     Source Type: Journal    
DOI: 10.1186/1750-1326-3-1     Document Type: Article

References (39)

1. A[beta]-Generating Enzymes: Recent Advances in [beta]- and [gamma]-Secretase Research. R Vassar M Citron, Neuron 2000 27 3 419 422 10.1016/S0896-6273(00)00051-9 11055423
2. A portrait of Alzheimer secretases - new features and familiar faces. WP Esler MS Wolfe, Science 2001 293 1449 1454 10.1126/science.1064638 11520976
3. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. J Hardy DJ Selkoe, Science 2002 297 5580 353 356 10.1126/science.1072994 12130773
4. Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red. A Lorenzo BA Yankner, Proc Natl Acad Sci U S A 1994 91 25 12243 12247 7991613 7991613 10.1073/pnas.91.25.12243
5. Diffusible, nonfibrillar ligands derived from Abeta 1-42 are potent central nervous system neurotoxins. MP Lambert AK Barlow BA Chromy C Edwards R Freed M Liosatos TE Morgan I Rozovsky B Trommer KL Viola P Wals C Zhang CE Finch GA Krafft WL Klein, Proc Natl Acad Sci U S A 1998 95 11 6448 6453 9600986 9600986 10.1073/pnas.95.11.6448
6. Targeting small A[beta] oligomers: the solution to an Alzheimer's disease conundrum? WL Klein GA Krafft CE Finch, Trends in Neurosciences 2001 24 4 219 224 10.1016/S0166-2236(00)01749-5 11250006
7. Synaptic vesicle proteins and regulated exocytosis. LA Elferink RH Scheller, J Cell Sci Suppl 1993 17 75 79 8144706
8. Synaptic loss in Alzheimer's disease and other dementias. JE Hamos LJ DeGennaro DA Drachman, Neurology 1989 39 3 355 361 2927643
9. Loss of synaptophysin-like immunoreactivity in the hippocampal formation is an early phenomenon in alzheimer's disease. O Heinonen H Soininen H Sorvari O Kosunen L Paljarvi E Koivisto Riekkinen, Neuroscience 1995 64 2 375 384 10.1016/0306-4522(94)00422-2 7700527
10. Alzheimer's Disease Is a Synaptic Failure. DJ Selkoe, Science 2002 298 5594 789 791 10.1126/science.1074069 12399581
11. Synapse loss in frontal cortex biopsies in Alzheimer's disease: correlation with cognitive severity. ST DeKosky SW Scheff, Ann Neurol 1990 27 5 457 464 2360787 2360787 10.1002/ana.410270502
12. Squalestatin protects neurons and reduces the activation of cytoplasmic phospholipase A2 by A[beta]1-42. C Bate A Williams, Neuropharmacology 2007 53 2 222 231 10.1016/j.neuropharm.2007.05.003 17583757
13. Influence of the severity of cognitive impairment on the effect of the Gnkgo biloba extract EGb 761 in Alzheimer's disease. PL Le Bars FM Velasco JM Ferguson EC Dessain M Kieser R Hoerr, Neuropsychobiology 2002 45 19 26 10.1159/000048668 11803237
14. Ginkgo biloba extract (EGb 761) and CNS functions: basic studies and clinical applications. FV DeFeudis K Drieu, CurrDrug Targets 2000 1 1 25 58 10.2174/1389450003349380
15. Pharmacological studies supporting the therapeutic use of Ginkgo biloba extract for Alzheimer's disease. B Ahlemeyer J Krieglstein, Pharmacopsychiatry 2003 36 Suppl 1 S8 S14 13130383 13130383
16. The efficacy of Ginkgo biloba on cognitive function in Alzheimer disease. BS Oken DM Storzbach JA Kaye, Arch Neurol 1998 55 11 1409 1415 9823823 9823823 10.1001/archneur.55.11.1409
17. Ginkgo for memory enhancement: a randomized controlled trial. PR Solomon F Adams A Silver J Zimmer R DeVeaux, JAMA 2002 288 7 835 840 10.1001/jama.288.7.835 12186600
18. Ginkgolide B inhibits the neurotoxicity of prions or amyloid-beta1-42. C Bate M Salmona A Williams, JNeuroinflammation 2004 1 1 4 10.1186/1742-2094-1-4
19. PAF antagonist ginkgolide B reduces postischemic neuronal damage in rat brain hippocampus. H Oberpichler D Sauer C Rossberg HD Mennel J Krieglstein, J Cereb Blood Flow Metab 1990 10 133 135 2298830 2298830
20. The role of platelet activating factor in prion and amyloid-β neurotoxicity. C Bate M Salmona A Williams, Neuroreport 2004 15 509 513 10.1097/00001756-200403010-00025 15094513
21. Myricetin and quercetin, the flavonoid constituents of Ginkgo biloba extract, greatly reduce oxidative metabolism in both resting and Ca(2+)-loaded brain neurons. Y Oyama PA Fuchs N Katayama K Noda, Brain Res 1994 635 125 129 10.1016/0006-8993(94)91431-1 8173947
22. Cellular membrane composition defines A beta-lipid interactions. SA Waschuk EA Elton AA Darabie PE Fraser JA McLaurin, J Biol Chem 2001 276 36 33561 33568 11438533 11438533 10.1074/jbc.M103598200
23. Activation of phospholipase A2 by amyloid beta-peptides in vitro. JY Lehtonen JM Holopainen PK Kinnunen, Biochemistry 1996 35 9407 9414 10.1021/bi960148o 8755719
24. Relative contribution of the de novo and remodelling pathways to the synthesis of platelet-activating factor in brain areas and during ischemia. E Francescangeli K Domanska-Janik G Goracci, J Lipid MediatCell Signal 1996 14 1-3 89 98 10.1016/0929-7855(96)01513-1
25. Distinct platelet-activating factor binding sites in synaptic endings and in intracellular membranes of rat cerebral cortex. VL Marcheselli MJ Rossowska MT Domingo P Braquet NG Bazan, J Biol Chem 1990 265 16 9140 9145 2160958
26. Enhancement of hippocampal excitatory synaptic transmission by platelet-activating factor. GD Clark LT Happel CF Zorumski NG Bazan, Neuron 1992 9 6 1211 1216 10.1016/0896-6273(92)90078-R 1334422
27. Platelet-activating factor as a potential retrograde messenger in CA1 hippocampal long-term potentiation. K Kato GD Clark NG Bazan CF Zorumski, Nature 1994 367 6459 175 179 10.1038/367175a0 8114914
28. Phospholipase A2-Generated Lipid Mediators in the Brain: The Good, the Bad, and the Ugly. AA Farooqui LA Horrocks, The Neuroscientist 2006 12 3 245 260 10.1177/1073858405285923 16684969
29. Platelet-activating factor receptor and signal transduction mechanisms. SD Shukla, FASEB J 1992 6 6 2296 2301 1312046
30. Comparison of three paf-acether receptor antagonist ginkgolides. R Korth D Nunez J Bidault J Benveniste, Eur J Pharmacol 1988 152 101 110 2850196 2850196 10.1016/0014-2999(88)90840-0
31. Structure-activity relationships for platelet-activating factor (PAF) and analogues reveal differences between PAF receptors on platelets and macrophages. AG Stewart G Grigoriadis, J Lipid Mediat 1991 4 3 299 308 1662547 1662547
32. CV-6209, a highly potent antagonist of platelet activating factor in vitro and in vivo. Z Terashita Y Imura M Takatani S Tsushima K Nishikawa, J Pharmacol Exp Ther 1987 242 1 263 268 3612533 3612533
33. Activation of EP4 receptors contributes to prostaglandin E2-mediated stimulation of renal sensory nerves. UC Kopp MZ Cicha K Nakamura RM Nusing LA Smith T Hokfelt, AmJPhysiol Renal Physiol 2004 287 6 F1269 F1282 10.1152/ajprenal.00230.2004
34. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. PL McGeer M Schulzer EG McGeer, Neurology 1996 47 2 425 432 8757015
35. Postsynaptically Synthesized Prostaglandin E2 (PGE2) Modulates Hippocampal Synaptic Transmission via a Presynaptic PGE2 EP2 Receptor. N Sang J Zhang V Marcheselli NG Bazan C Chen, J Neuroscience 2005 25 43 9858 9870 16251433 10.1523/JNEUROSCI.2392-05.2005
36. Prostaglandin E(2) induces caspase-dependent apoptosis in rat cortical cells. T Takadera H Yumoto Y Tozuka T Ohyashiki, Neurosci Lett 2002 317 2 61 64 11755240 11755240 10.1016/S0304-3940(01)02449-1
37. Quantitative determination of major active components in Ginkgo biloba dietary supplements by liquid chromatography/mass spectrometry. S Ding E Dudley S Plummer J Tang RP Newton AG Brenton, Rapid Commun Mass Spectrom 2006 20 18 2753 2760 10.1002/rcm.2646 16921563
38. Deciphering the Molecular Basis of Memory Failure in Alzheimer's Disease. DM Walsh DJ Selkoe, Neuron 2004 44 1 181 193 10.1016/j.neuron.2004.09.010 15450169
39. Isolation and culture of adult rat hippocampal neurons. GJ Brewer, J Neurosci Meth 1997 71 2 143 155 10.1016/S0165-0270(96)00136-7